Topic:
R&D
Latest Headlines
Latest Headlines
Touch-sensitive robot arm envisioned, in part, as patient care device
Roboticists at the Georgia Institute of Technology's Department of Biomedical Engineering have come up with a robot arm that is touch-sensitive and can move and find various objects
'Spider' protein can deliver stable vaccines in high concentration
German researchers are using the highly stable structure of a uniquely shaped human immune protein as a model for high-concentration vaccine delivery.
Biotech startup hustles new Alzheimer's program to the clinic
Back in early 2012, a number of physicians around the U.S. began fielding some unusual requests from Alzheimer's patients for a prescription covering Targretin (bexarotene), a cancer drug sold by Eisai.
Johnson & Johnson, Evotec bask in Harvard's breaking diabetes discovery
The German biotech Evotec and Johnson & Johnson have the inside track on drug development based on a Harvard lab's discovery of a hormone that spurs replication of insulin-producing beta cells. The finding opens the door to a novel mechanism for treating diabetes, yet researchers caution that the impressive data in mice have some time to go before they are replicated in humans.
Industry Voices: Time to Take Fecal Transplantation Seriously
The NEJM 's recent publication of the first randomized, controlled trial of fecal transplantation (FT) is a big deal for research of the human microbiome, which is the community of microbes that colonize the body and impact infection, immune reactions and other aspects of our health. I can't think of a better response to the warnings of hype for this new field of research than convincing clinical data validating microbiome modulation as a therapeutic approach. More >>
UPDATED: Theravance to split into two biotech groups as GSK drugs progress
Theravance announced Thursday afternoon that it plans to break apart into two publicly traded companies: a company dubbed Royalty Management that will take over Theravance's late-stage respiratory drugs and another called Theravance Biopharma focused on small-molecule R&D.
Bristol-Myers gains FDA's 'breakthrough' track in race for hep C drug approval
The big biotech reported in its quarterly statement that the agency has provided the coveted "breakthrough" status for a combination of daclatasvir with two other direct-acting antivirals, asunaprevir, an NS3 protease inhibitor and BMS-791325, an NS5B non-nucleoside polymerase inhibitor.
Radius nabs $43M round for PhIII bone-building drug
The Cambridge, MA-based developer, which is focused on new therapies for osteoporosis, says that F2 Biosciences III stepped up to lead the latest round of $43 million.
Eli Lilly slugs it out with J&J on Alzheimer's drug patent claim
With a new late-stage study being prepped for the Alzheimer's drug solanezumab, Eli Lilly found itself in a London courtroom this week defending itself against a patent claim by Johnson & Johnson, one of its chief rivals in the risky game of Alzheimer's drug development.
AstraZeneca's PhIII chief scouts for blockbuster deals as revenue slides
AstraZeneca today had another big round of dismal revenue numbers to explain today. With generic rivals tearing at some of its key franchises, the pharma giant reported a 13% drop in revenue for the first quarter.
